ClinicalTrials.gg
RecruitingNCT07511218Updated Jul 21, 2026

A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants

A Phase 1 interventional study of AHB-171 Injection and Placebo in Chronic Hepatitis B Infection, sponsored by Ausper Biopharma Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Ausper Biopharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. — 8 open to participants now, 11 under way, 1 of them phase 3. Hepatitis B, Chronic · Ausper Biopharma Co., Ltd..

Planned enrollment
6th of 12
110 · median 110
Started
2026
with 4 others
Phase 1
3 of 13
3 open now
Primary completion
2027-12
later than 7 of 10 live
Registered
9th of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 9th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

8 of the 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Ausper Biopharma Co., Ltd., or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.

03

Conditions studied

  • Chronic Hepatitis B Infection

Browse trials for

Keywords

  • Hepatitis B, Chronic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Participants:
  • Male or female participants, aged 18-55 years old (inclusive);
  • between 18.0 and 28.0 kg/m\^2 (inclusive);
  • Laboratory safety tests during the screening period, 12-lead (ECG), abdominal ultrasound, thyroid ultrasound, chest anteroposterior position, etc., are assessed by the investigatoras normal or abnormal without clinical significance;
  • Female participants of must not be pregnant or lactating, must have a negative pregnancy test at screening, and must agree to use effective methods and refrain from donating eggs from screening until 6 months after the last dose of the study drug.
  • Male participants must agree to use highly effective contraceptive methods (to ensure effective contraception for their female partners of childbearing potential) and refrain from donating sperm from screening until 6 months after the last dose of the study drug. Liver and kidney function tests meet the requirements at the time of screening.
  • CHB Participants:
  • Male or female participants, aged 18-65 years old (inclusive);
  • Body mass index between 18.0 and 32.0 kg/m\^2 (inclusive);
  • Participants who take effective contraceptive measures as required;
  • > 100 IU/mL and ≤ 3000 IU/mL, and HBV DNA \< 100 IU/mL at screening.
  • Have received stable treatment with NA for at least 6 months and stable on the same NA for at least 3 months before screening.

Exclusion criteria

Exclusion Criteria:

  • Healthy Participants:
  • Currently participating in another study, or within 5 half-lives/3 months of the last dose of a previous product.
  • Presence diseases (cardiovascular, neurological, renal, immunological, metabolic, etc.) or malignant tumors.- Major surgery or severe trauma within the past 6 months.
  • Acute infection (e.g., influenza, gastroenteritis) within 14 days; vaccination within 28 days prior to screening.
  • Allergy to any investigational drug component.
  • Heavy Smoking (> 5 cigarettes/day); history of drug/alcohol abuse; consumption of caffeine or alcohol within 48 hours before dosing.
  • Blood donation/loss ≥400 mL or transfusion within 12 weeks, or plan to donate during study.
  • Abdominal skin issues that may affect drug injection/observation.
  • Positive for , , , or syphilis.
  • abnormality or TdP risk factors.
  • Any condition judged unsuitable by investigator.
  • CHB Participants:
  • Currently participating in another study, or within 5 half-lives/3 months of the last dose of a previous investigational product.
  • Presence of ascites, gastrointestinal bleeding, hepatic encephalopathy, or varices.
  • History or suspicion of hepatocellular carcinoma (HCC); AFP > 50 ng/mL.
  • Diagnosed or Suspected cirrhosis within 12 months.
  • History of transplantation, diseases, or severe systemic diseases (besides chronic HBV).
  • Use of ASO, siRNA (oligonucleotide therapies), or interferon within 12 months.
  • Major injury/surgery within 6 months, planned surgery during study, or acute infection within 14 days.
  • Allergy to any investigational drug component.
  • Blood donation/loss ≥400 mL or transfusion within 12 weeks, or plan to donate during study.
  • Abdominal skin issues that may affect drug injection/observation.
  • Key laboratory result not suitable for clinical trial.
  • HIV, HCV, or active syphilis infection; uncured hepatitis A, D, or E.
  • Clinically significant ECG abnormality or TdP risk factors.
  • Any condition judged unsuitable by investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    AHB-171 and placebo in CHB (Part B: MAD)

    Drug: AHB-171 Injection Drug: Placebo Drug: Nucleos(t)ide Analogue (NA) Background treatment

    Drug: AHB-171 Injection · Drug: Placebo · Drug: Nucleos(t)ide Analogue (NA)

  • Experimental
    AHB-171 and placebo in HP(Part A: SAD)

    Drug: AHB-171Injection Drug: Placebo

    Drug: AHB-171 Injection · Drug: Placebo

Interventions

  • AHB-171 Injection is adminstrated via subcutaneous injection

  • DrugPlacebo

    Placebo is admistrated via subcutaneous injection

  • DrugNucleos(t)ide Analogue (NA)

    Oral administration

06

What researchers measure

Primary outcomes

  1. Part A & Part B Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  2. Severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  3. Change from baseline in laboratory tests

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  4. Change from baseline in physical examinations

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  5. Change from baseline in vital signs

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  6. Change from baseline in electrocardiograms (ECGs)

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  7. Part A:Plasma Cmax of AHB-171

    Time frame: Up to Day 8

  8. Part A:Plasma Tmax of AHB-171

    Time frame: Up to Day 8

  9. Part A Plasma AUC of AHB-171

    Time frame: Up to Day 8

  10. Part A Plasma t1/2 of AHB-171

    Time frame: Up to Day 8

  11. Proportion of participants with clinically significant abnormalities in laboratory tests

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  12. Proportion of participants with clinically significant abnormalities in electrocardiograms (ECGs)

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  13. Proportion of participants with physical examinations

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

  14. Proportion of participants with other vital signs

    Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

Secondary outcomes

  1. Part A & Part B:Fraction excreted in urine in percentage for AHB-171

    Time frame: Up to Day 3 in Part A; Up to Day 30 in Part B

  2. Part A & Part B:Amount excreted in urine for AHB-171

    Time frame: Up to Day 3 in Part A; Up to Day 30 in Part B

  3. Part A & Part B:Renal clearance for AHB-171

    Time frame: Up to Day 3 in Part A; Up to Day 30 in Part B

  4. Part A & Part B: Immunogenicity: The number of participants develop anti-drug antibodies (ADA) against AHB-171 and the ADA antibody titer

    Time frame: Up to 16 weeks in Part A; Up to 48 weeks in Part B

  5. Part B:Plasma Cmax of AHB-171

    Time frame: Up to Day 31

  6. Part B:Plasma Tmax of AHB-171

    Time frame: Up to Day 31

  7. Part B Plasma AUC of AHB-171

    Time frame: Up to Day 31

  8. Part B Plasma t1/2 of AHB-171

    Time frame: Up to Day 31

  9. Part B: Proportion of CHB who achieved hepatitis B surface antigen (HBsAg) clearance

    Time frame: Up to 48 weeks

  10. Part B: HBsAg Decline in CHB Participants at each assessment time point

    Time frame: Up to 48 weeks

  11. Part B:Proportion of participants with HBsAg < 1 IU/mL, < 10 IU/mL, and < 100 IU/mL at each assessment time point.

    Time frame: Up to 48 weeks

  12. Part B Proportion of participants achieve seroconversion to anti-HBs (HBsAb >10 IU/L) after HBsAg loss.

    Time frame: Up to 48 weeks

  13. Part B Proportion of participants with HBV DNA < LLOQ (10 IU/mL)

    Time frame: Up to 48 weeks

  14. Part B Proportion of participants with HBsAg < LOD and HBV DNA < LLOQ at each assessment time point

    Time frame: Up to 48 weeks

  15. Part B Serum levels of HBsAg, HBV DNA, HBV RNA, HBcrAg, HBsAb , HBeAb , HBeAg

    Time frame: Up to 48 weeks

  16. Part B The level of ALT.

    Time frame: Up to 48 weeks

  17. PartB: Proportion of participants achieving ALT normalization and time to ALT normalization among those with baseline ALT > ULN.

    Time frame: Up to 48 weeks

  18. Part B Correlation between pharmacokinetic and pharmacodynamic parameters of AHB-171

    Time frame: Up to 48 weeks

07

Study locations

2 of 2 sites recruiting
  • AusperBio Investigational Site
    Ch’ang-ch’un, Jilin, China
    Recruiting
    • Bella Lu · Contactclinicaltrial@ausperbio.com · 0571-86959519
    • Yanhua Ding · Principal investigator
    • Junqi Niu · Principal investigator
  • AusperBio Investigational Site
    Hangzhou, Zhejiang 310052, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 20 months is above that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 6, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07511218
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Apr 13, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 21, 2026

Study contacts

Bella Lu
Contact
clinicaltrial@ausperbio.com
0571-86959519

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AHB-171

Start the discussion